Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

This publication has 12 references indexed in Scilit:

• Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance
  Cancer Research, 2005
• Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
  Oncogene, 2003
• Reversal of breast cancer resistance protein (BCRP/ABCG2)‐mediated drug resistance by novobiocin, a coumermycin antibiotic
  International Journal of Cancer, 2003
• Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2003
• Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors
  Annals of Oncology, 2003
• Mammalian ABC Transporters in Health and Disease
  Annual Review of Biochemistry, 2002
• Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
  Biochemical and Biophysical Research Communications, 2001
• Epidermal growth factor-related peptides and their receptors in human malignancies
  Published by Elsevier ,2000
• Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents
  International Journal of Cancer, 1999
• DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant
  International Journal of Cancer, 1997